Donafenib: First Approval

Donafenib (Zepsun (R), ...(R)), a deuterium derivative of sorafenib, is an oral small molecule multikinase inhibitor of multiple receptor kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and Raf kinases. Donafenib is being developed by Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Zelgen) for the treatment of various cancers, including hepatocellular carcinoma, colorectal cancer and thyroid cancer. In June 2021, donafenib received its first approval in China for the treatment of patients with unresectable hepatocellular carcinoma who have not previously received systemic treatment. This article summarizes the milestones in the development of donafenib leading to this first approval for use in unresectable hepatocellular carcinoma.

Automated summary

Donafenib is an oral multikinase inhibitor developed by Suzhou Zelgen Biopharmaceuticals Co., Ltd. for the treatment of various cancers, including hepatocellular carcinoma. It recently received its first approval in China for unresectable hepatocellular carcinoma, marking a significant milestone in its development.